The cytochrome P450s are a superfamily of enzymes that are found in all kingdoms of living organisms, and typically catalyze the oxidative addition of atomic oxygen to an unactivated C-C or C-H bond. Over 8000 nonredundant sequences of putative and confirmed P450 enzymes have been identified, but three-dimensional structures have been determined for only a small fraction of these. While all P450 enzymes for which structures have been determined share a common global fold, the flexibility and modularity of structure around the active site account for the ability of P450 enzymes to accommodate a vast number of structurally dissimilar substrates and support a wide range of selective oxidations. In this review, known P450 structures are compared, and some structural criteria for prediction of substrate selectivity and reaction type are suggested. The importance of dynamic processes such as redox-dependent and effector-induced conformational changes in determining catalytic competence and regio- and stereoselectivity is discussed, and noncrystallographic methods for characterizing P450 structures and dynamics, in particular, mass spectrometry and nuclear magnetic resonance spectroscopy are reviewed. Antioxid. Redox Signal. 13, 1273–1296.
AldagC, GromovIA, Garcia–RubioI, von KoenigK, SchlichtingI, JaunB, HilvertD. Probing the role of the proximal heme ligand in cytochrome P450cam by recombinant incorporation of selenocysteine. Proc Natl Acad Sci USA, 106:5481–5486. 2009.
2.
.AltschulSF, MaddenTL, SchafferAA, ZhangJH, ZhangZ, MillerW, LipmanDJ. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res, 25:3389–3402. 1997.
3.
AndersenJF, TatsutaK, GunjiH, IshiyamaT, HutchinsonCR. Substrate-apecificity of 6-Deoxyerythronolide-B hydroxylase, a bacterial cytochrome P450 of erythromycin-a biosynthesis. Biochemistry, 32:1905–1913. 1993.
4.
ArimotoR. Computational models for predicting interactions with cytochrome P450 enzyme. Current Topics Med Chem, 6:1609–1618. 2006.
5.
AsciuttoEK, MaduraJD, PochapskySS, OuYangB, PochapskyTC. Structural and dynamic implications of an effector-induced backbone amide cis-trans isomerization in cytochrome P450(cam)J Mol Biol, 388:801–814. 2009.
6.
BaiJPF. Ongoing challenges in drug interaction safety: From exposure to pharmacogenomics. Drug Metab Pharmacokin, 25:62–71. 2010.
7.
BelinP, Le DuMH, FieldingA, LequinO, JacquetM, CharbonnierJB, LecoqA, ThaiR, CourconM, MassonC, DugaveC, GenetR, PernodetJL, GondryM. Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis. Proc Natl Acad Sci USA, 106:7426–7431. 2009.
8.
BellSG, XuF, ForwardI, BartlamM, RaoZ, WongLL. Crystal structure of CYP199A2, a para-substituted benzoic acid oxidizing cytochrome P450 from Rhodopseudomonas palustris. J Mol Biol, 383:561–574. 2008.
9.
BlakeCCF, KoenigDF, MairGA, NorthACT, PhillipsDC, SarmaVR. Structure of hen egg-white lysozyme: A 3-dimensional fourier Ssynthesis at 2 Å resolution. Nature, 206:757. 1965.
10.
CameronMD, WenB, AllenKE, RobertsAG, SchumanJT, CampbellAP, KunzeKL, NelsonSD. Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: A NMR T-1 paramagnetic relaxation study. Biochemistry, 44:14143–14151. 2005.
ChenLM, BruggerK, SkovgaardM, RedderP, SheQX, TorarinssonE, GreveB, AwayezM, ZibatA, KlenkHP, GarrettRA. The genome of Sulfolobus acidocaldarius, a model organism of the Crenarchaeota. J Bacteriol, 187:4992–4999. 2005.
13.
ChenS, ZhouDJ. Functional domains of aromatase cytochrome-P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis Eexperiments. J Biol Chem, 267:22587–22594. 1992.
14.
ClarkJP, MilesCS, MowatCG, WalkinshawMD, ReidGA, DaffSN, ChapmanSK. The role of Thr268 and Phe393 in cytochrome P450 BM3. J Inorg Biochem, 100:1075–1090. 2006.
15.
CryleMJ, SchlichtingI. Structural insights from a P450 Carrier Protein complex reveal how specificity is achieved in the P450(BioI) ACP complex. Proc Natl Acad Sci USA, 105:15696–15701. 2008.
16.
Cupp–VickeryJ, AndersonR, HatzirisZ. Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc Natl Acad Sci USA, 97:3050–3055. 2000.
17.
Cupp–VickeryJR, GarciaC, HofacreA, McGee–EstradaK. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J Mol Biol, 311:101–110. 2001.
18.
Cupp–VickeryJR, PoulosTL. Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Nat Struct Biol, 2:144–153. 1995.
19.
de GraafC, OostenbrinkC, KeizersPHJ, van Vugt-LussenburgBMA, van WaterschootRAB, Tschirret-GuthRA, CommandeurJNM, VermeulenNPE. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Current Drug Metabolism, 8:59–77. 2007.
20.
DeLanoWL. The PyMOL Molecular Graphics System. 2008.
21.
DeVoreNM, SmithBD, UrbanMJ, ScottEE. Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes. Drug Metab Dispos, 36:2582–2590. 2008.
22.
DmochowskiIJ, CraneBR, WilkerJJ, WinklerJR, GrayHB. Optical detection of cytochrome P450 by sensitizer-linked substrates. Proc Natl Acad Sci USA, 96:12987–12990. 1999.
23.
DunnAR, DmochowskiIJ, BilwesAM, GrayHB, CraneBR. Probing the open state of cytochrome P450cam with ruthenium-linker substrates. Proc Natl Acad Sci USA, 98:12420–12425. 2001.
24.
EddineAN, von KriesJP, PodustMV, WarrierT, KaufmannSH, PodustLM. X-ray structure of 4,4'-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51)J Biol Chem, 283:15152–15159. 2008.
25.
EkroosM, SjogrenT. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA, 103:13682–13687. 2006.
26.
FedorovR, GhoshDK, SchlichtingI. Crystal structures of cyanide complexes of P450cam and the oxygenase domain of inducible nitric oxide synthase-structural models of the short-lived oxygen complexes. Arch Biochem Biophys, 409:25–31. 2003.
27.
FruetelJA, MackmanRL, PetersonJA, Ortiz de MontellanoPR. Relationship of active site topology to substrate specificity for cytochrome P450terp (CYP108)J Biol Chem, 269:28815–28821. 1994.
28.
GaySC, SunL, MaekawaK, HalpertJR, StoutCD. Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: Ligand-induced structural response through alpha-helical repositioning. Biochemistry, 48:4762–4771. 2009.
29.
GhoshD, GriswoldJ, ErmanM, PangbornW. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature, 457:219–U119. 2009.
30.
GirvanHM, SewardHE, ToogoodHS, CheesmanMR, LeysD, MunroAW. Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3. J Biol Chem, 282:564–572. 2007.
GotohO. Substrate recognition sites in cytochrome-P450 family-2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem, 267:83–90. 1992.
33.
HainesDC, ChenB, TomchickDR, BondlelaM, HegdeA, MachiusM, PetersonJA. Crystal structure of inhibitor-bound P450BM-3 reveals open conformation of substrate access channel. Biochemistry, 47:3662–3670. 2008.
34.
HainesDC, TomchickDR, MachiusM, PetersonJA. Pivotal role of water in the mechanism of P450BM-3. Biochemistry, 40:13456–13465. 2001.
35.
HamuroY, MolnarKS, CoalesSJ, OuYangB, SimorellisAK, PochapskyTC. Hydrogen-deuterium exchange mass spectrometry for investigation of backbone dynamics of oxidized and reduced cytochrome P450(cam)J Inorg Biochem, 102:364–370. 2008.
36.
HannemannF, BichetA, EwenKM, BernhardtR. Cytochrome P450 systems. Biological variations of electron transport chains. Biochim Biophys Acta-Gen Subj, 1770:330–344. 2007.
37.
HasemannCA, RavichandranKG, PetersonJA, DeisenhoferJ. Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. J Mol Biol, 236:1169–1185. 1994.
38.
HayashiK, SugimotoH, ShinkyoR, YamadaM, IkedaS, IkushiroS, KamakuraM, ShiroY, SakakiT. Structure-based design of a highly active vitamin D hydroxylase from Streptomyces griseolus CYP105A1. Biochemistry, 47:11964–11972. 2008.
39.
HegdeA, HainesDC, BondlelaM, ChenB, SchafferN, TomchickDR, MachiusM, NguyenH, ChowdharyPK, StewartL, LopezC, PetersonJA. Interactions of substrates at the surface of P450s can greatly enhance substrate potency. Biochemistry, 46:14010–14017. 2007.
40.
HlavicaP. Functional interaction of nitrogenous organic bases with cytochrome P450: A critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines. Biochim Biophys Acta-Proteins Proteomics, 1764:645–670. 2006.
41.
HoWW, LiH, NishidaCR, de MontellanoPR, PoulosTL. Crystal structure and properties of CYP231A2 from the thermoacidophilic archaeon Picrophilus torridus. Biochemistry, 47:2071–2079. 2008.
42.
HsuMH, GriffinKJ, WangY, KemperB, JohnsonEF. A single amino acid substitution confers progesterone 6-beta-hydroxylase activity to rabbit cytochrome P450 2C3. J Biol Chem, 268:6939–6944. 1993.
43.
HuangWC, WestlakeAC, MarechalJD, JoyceMG, MoodyPC, RobertsGC. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency. J Mol Biol, 373:633–651. 2007.
44.
HummelMA, GannettPM, AguilarJ, TracyTS. Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Arch Biochem Biophys, 475:175–183. 2008.
45.
HutterMC. In silico prediction of drug properties. Curr Med Chem, 16:189–202. 2009.
46.
IwasakiM, DardenTA, PedersenLG, DavisDG, JuvonenRO, SueyoshiT, NegishiM. Engineering mouse P450coh to a novel corticosterone 15-alpha-hydroxylase and modeling steroid-binding orientation in the substrate pocket. J Biol Chem, 268:759–762. 1993.
47.
JohnsonEF, WesterMR, StoutCD. The structure of microsomal cytochrome P450 2C5: A steroid and drug metabolizing enzyme. Endocrine Res, 28:435–441. 2002.
48.
JovanovicT, HarrisM, McDermottAE. Cytochrome P450BM-3 in complex with its substrate: Temperature-dependent spin state equilibria in the oxidized and reduced states. Applied Magnetic Resonance, 31:411–429. 2007.
49.
JovanovicT, McDermottAE. Observation of ligand binding to cytochrome P450 BM-3 by means of solid-state NMR spectroscopy. J Am Chem Soc, 127:13816–13821. 2005.
50.
KendrewJC, BodoG, DintzisHM, ParrishRG, WyckoffH, PhillipsDC. 3-dimensional model of the myoglobin molecule obtained by X-ray analysis. Nature, 181:662–666. 1958.
51.
KijacAZ, LiY, SligarSG, RienstraCM. Magic-angle spinning solid-state NMR Spectroscopy of nanodisc-embedded human CYP3A4. Biochemistry, 46:13696–13703. 2007.
52.
KooLS, ImmoosCE, CohenMS, FarmerPJ, de MontellanoPRO. Enhanced electron transfer and lauric acid hydroxylation by site-directed mutagenesis of CYP119. J Am Chem Soc, 124:5684–5691. 2002.
53.
KudoT, TakayaN, ParkSY, ShiroY, ShounH. A positively charged cluster formed in the heme-distal pocket of cytochrome P450nor is essential for interaction with NADH. J Biol Chem, 276:5020–5026. 2001.
54.
KuhnelK, KeN, CryleMJ, SligarSG, SchulerMA, SchlichtingI. Crystal structures of substrate-free and retinoic acid-bound cyanobacterial cytochrome P450 CYP120A1. Biochemistry, 31:31. 2008.
55.
LeeDS, NiocheP, HambergM, RamanCS. Structural insights into the evolutionary paths of oxylipin biosynthetic enzymes. Nature, 455:363–368. 2008.
56.
LeeDS, YamadaA, SugimotoH, MatsunagaI, OguraH, IchiharaK, AdachiS, ParkSY, ShiroY. Substrate recognition and molecular mechanism of fatty acid hydroxylation by cytochrome P450 from Bacillus subtilis. Crystallographic, spectroscopic, and mutational studies. J Biol Chem, 278:9761–9767. 2003.
57.
LepeshevaGI, ParkHW, HargroveTY, VanhollebekeB, WawrzakZ, ChaudhuriM, VillaltaF, WatermanMR. Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections. J Biol Chem, 285:1773–1780. 2010.
58.
LepeshevaGI, VirusC, WatermanMR. Conservation in the CYP51 family. Role of the B ' helix/BC loop and helices F and G in enzymatic function. Biochemistry, 42:9091–9101. 2003.
59.
LewisDFV, ItoY. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity. Xenobiotica, 39:625–635. 2009.
60.
LewisDFV, ItoY, GoldfarbPS. Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. Curr Drug Metab, 7:589–598. 2006.
61.
LewisDFV, ItoY, GoldfarbPS. Structural modelling of the human drug-metabolizing cytochromes P450. Curr Med Chem, 13:2645–2652. 2006.
62.
LeysD, MowatCG, McLeanKJ, RichmondA, ChapmanSK, WalkinshawMD, MunroAW. Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 Å reveals novel features of cytochrome P450. J Biol Chem, 278:5141–5147. 2003.
63.
LiH, PoulosTL. Modeling protein-substrate interactions in the heme domain of cytochrome P450(BM-3)Acta Crystallogr D Biol Crystallogr, 51:21–32. 1995.
64.
LiH, PoulosTL. The structure of the cytochrome P450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat Struct Biol, 4:140–146. 1997.
65.
LiL, ChangZ, PanZ, FuZQ, WangX. Modes of heme binding and substrate access for cytochrome P450 CYP74A revealed by crystal structures of allene oxide synthase. Proc Natl Acad Sci USA, 105:13883–13888. 2008.
66.
LiS, OuelletH, ShermanDH, PodustLM. Analysis of transient and catalytic desosamine-binding pockets in cytochrome P450 PikC from Streptomyces venezuelae. J Biol Chem, 284:5723–5730. 2009.
67.
LiSY, ChaulagainMR, KnauffAR, PodustLM, MontgomeryJ, ShermanDH. Selective oxidation of carbolide C-H bonds by an engineered macrolide P450 mono-oxygenase. Proc Natl Acad Sci USA, 106:18469–18474. 2009.
68.
LiYC, ChiangCW, YehHC, HsuPY, WhitbyFG, WangLH, ChanNL. Structures of prostacyclin synthase and its complexes with substrate analog and inhibitor reveal a ligand-specific heme conformation change. J Biol Chem, 283:2917–2926. 2008.
69.
LiaoWL, DodderNG, MastN, PikulevaIA, TurkoIV. Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry. Biochemistry, 48:4150–4158. 2009.
70.
LipscombJD, SligarSG, NamtvedtMJ, GunsalusIC. Autooxidation and Hhydroxylation reactions of oxygenated cytochrome P450cam. J Biol Chem, 251:1116–1124. 1976.
71.
LudemannSK, LounnasV, WadeRC. How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms. J Mol Biol, 303:797–811. 2000.
72.
LudemannSK, LounnasV, WadeRC. How do substrates enter and products exit the buried active site of cytochrome P450cam? 2. Steered molecular dynamics and adiabatic mapping of substrate pathways. J Mol Biol, 303:813–830. 2000.
73.
LyonsTA, RatnaswamyG, PochapskyTC. Redox-dependent dynamics of putidaredoxin characterized by amide proton exchange. Protein Science, 5:627–639. 1996.
74.
MakinoM, SugimotoH, ShiroY, AsamizuS, OnakaH, NaganoS. Crystal structures and catalytic mechanism of cytochrome P450 StaP that produces the indolocarbazole skeleton. Proc Natl Acad Sci USA, 104:11591–11596. 2007.
75.
MakrisTM, von KoenigK, SchlichtingI, SligarSG. Alteration of P450 distal pocket solvent leads to impaired proton delivery and changes in heme geometry. Biochemistry, 46:14129–14140. 2007.
76.
MakrisTM, von KoenigK, SchlichtingI, SligarSG. The status of high-valent metal oxo complexes in the P450 cytochromes. J Inorg Biochem, 100:507–518. 2006.
77.
MansuyD. Biocatalysis and substrate chemodiversity: Adaptation of aerobic living organisms to their chemical environment. Catalysis Today, 138:2–8. 2008.
78.
MastN, LiaoWL, PikulevaIA, TurkoIV. Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase. Arch Biochem Biophys, 483:81–89. 2009.
79.
MastN, WhiteMA, BjorkhemI, JohnsonEF, StoutCD, PikulevaIA. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci USA, 105:9546–9551. 2008.
80.
McCulloughCR, PullelaPK, ImSC, WaskellL, SemDS. C-13-methyl isocyanide as an NMR probe for cytochrome P450 active sites. J Biomol NMR, 43:171–178. 2009.
81.
McLeanKJ, CarrollP, LewisDG, DunfordAJ, SewardHE, NeeliR, CheesmanMR, MarsollierL, DouglasP, SmithWE, RosenkrandsI, ColeST, LeysD, ParishT, MunroAW. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. J Biol Chem, 283:33406–33416. 2008.
82.
McLeanKJ, LafiteP, LevyC, CheesmanMR, MastN, PikulevaIA, LeysD, MunroAW. The structure of Mycobacterium tuberculosis CYP125: Molecular basis for cholesterol binding in a P450 needed for host infection. J Biol Chem, 284:35524–35533. 2009.
83.
ModiS, PaineMJ, SutcliffeMJ, LianLY, PrimroseWU, WolfCR, RobertsGCK. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry, 35:4540–4550. 1996.
84.
ModiS, SutcliffeMJ, PrimroseWU, LianLY, RobertsGCK. The catalytic mechanism of cytochrome P450 BM3 involves a 6 angstrom movement of the bound substrate on reduction. Nature Structural Biology, 3:414–417. 1996.
85.
MyersTG, ThummelKE, KalhornTF, NelsonSD. Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by C13 NMR and N15 NMR relaxation studies. J Med Chem, 37:860–867. 1994.
86.
NaganoS, Cupp–VickeryJR, PoulosTL. Crystal structures of the ferrous dioxygen complex of wild-type cytochrome P450eryF and its mutants, A245S and A245T: investigation of the proton transfer system in P450eryF. J Biol Chem, 280:22102–22107. 2005.
87.
NaganoS, LiH, ShimizuH, NishidaC, OguraH, Ortiz de MontellanoPR, PoulosTL. Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK. J Biol Chem, 278:44886–44893. 2003.
88.
NaganoS, PoulosTL. Crystallographic study on the dioxygen complex of wild-type and mutant cytochrome P450cam. Implications for the dioxygen activation mechanism. J Biol Chem, 280:31659–31663. 2005.
89.
NaganoS, ToshaT, IshimoriK, MorishimaI, PoulosTL. Crystal structure of the cytochrome P450cam mutant that exhibits the same spectral perturbations induced by putidaredoxin binding. J Biol Chem, 279:42844–42849. 2004.
90.
OkuY, OhtakiA, KamitoriS, NakamuraN, YohdaM, OhnoH, KawarabayasiY. Structure and direct electrochemistry of cytochrome P450 from the thermoacidophilic crenarchaeon, Sulfolobus tokodaii strain 7. J Inorg Biochem, 98:1194–1199. 2004.
91.
OshimaR, FushinobuS, SuF, ZhangL, TakayaN, ShounH. Structural evidence for direct hydride transfer from NADH to cytochrome P450nor. J Mol Biol, 342:207–217. 2004.
92.
OstTW, ClarkJ, MowatCG, MilesCS, WalkinshawMD, ReidGA, ChapmanSK, DaffS. Oxygen activation and electron transfer in flavocytochrome P450 BM3. J Am Chem Soc, 125:15010–15020. 2003.
93.
OstTW, MunroAW, MowatCG, TaylorPR, PesseguieroA, FulcoAJ, ChoAK, CheesmanMA, WalkinshawMD, ChapmanSK. Structural and spectroscopic analysis of the F393H mutant of flavocytochrome P450 BM3. Biochemistry, 40:13430–13438. 2001.
94.
OuelletH, PodustLM, de MontellanoPR. Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem, 283:5069–5080. 2008.
95.
OuYangB, PochapskySS, DangM, PochapskyTC. A functional proline switch in cytochrome P450(cam)Structure, 16:916–923. 2008.
PochapskySS, PochapskyTC, WeiJW. A model for effector activity in a highly specific biological electron transfer complex: The cytochrome P450(cam)-putidaredoxin couple. Biochemistry, 42:5649–5656. 2003.
100.
PochapskyTC, LyonsTA, KazanisS, ArakakiT, RatnaswamyG. A structure-based model for cytochrome P450(cam)-putidaredoxin interactions. Biochimie, 78:723–733. 1996.
101.
PodustLM, BachH, KimY, LambDC, AraseM, ShermanDH, KellySL, WatermanMR, SchochGA, YanoJK, WesterMR, GriffinKJ, StoutCD, JohnsonEF. Comparison of the 1.85 Å structure of CYP154A1 from Streptomyces coelicolor A3(2) with the closely related CYP154C1 and CYPs from antibiotic biosynthetic pathways. Protein Sci, 13:255–268. 2004.
102.
PodustLM, KimY, AraseM, NeelyBA, BeckBJ, BachH, ShermanDH, LambDC, KellySL, WatermanMR. The 1.92-A structure of Streptomyces coelicolor A3(2) CYP154C1. A new monooxygenase that functionalizes macrolide ring systems. J Biol Chem, 278:12214–12221. 2003.
103.
PodustLM, PoulosTL, WatermanMR. Crystal structure of cytochrome P450 14-alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA, 98:3068–3073. 2001.
104.
PodustLM, von KriesJP, EddineAN, KimY, YermalitskayaLV, KuehneR, OuelletH, WarrierT, AltekosterM, LeeJS, RademannJ, OschkinatH, KaufmannSH, WatermanMR. Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob Agents Chemother, 51:3915–3923. 2007.
105.
PorubskyPR, MeneelyKM, ScottEE. Structures of human cytochrome P450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem, 283:33698–33707. 2008.
106.
PoulosTL. Modeling of mammalian P450s on basis of P450cam X-ray structure. Methods Enzymol, 206:11–30. 1991.
107.
PoulosTL. Structural biology of P450-oxy complexes. Drug Metab Rev, 39:557–566. 2007.
PoulosTL, HowardAJ. Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P450cam. Biochemistry, 26:8165–8174. 1987.
111.
PrusisP, AfzeliusL. Improvement of site of metabolism predictions for CYP3A4 by using discriminant analysis of compound preference of CYP3A4 X-ray structural conformers and subsequent docking. QSAR Comb Sci, 28:865–868. 2009.
112.
PylypenkoO, VitaliF, ZerbeK, RobinsonJA, SchlichtingI. Crystal structure of OxyC, a cytochrome P450 implicated in an oxidative C-C coupling reaction during vancomycin biosynthesis. J Biol Chem, 278:46727–46733. 2003.
RaagR, MartinisSA, SligarSG, PoulosTL. Crystal structure of the cytochrome P450cam active site mutant Thr252Ala. Biochemistry, 30:11420–11429. 1991.
115.
RaagR, PoulosTL. Crystal structure of the carbon monoxide-substrate-cytochrome P450CAM ternary complex. Biochemistry, 28:7586–7592. 1989.
116.
RaagR, PoulosTL. Crystal structures of cytochrome P450cam complexed with camphane, thiocamphor, and adamantane: Factors controlling P450 substrate hydroxylation. Biochemistry, 30:2674–2684. 1991.
117.
RaagR, PoulosTL. The structural basis for substrate-induced changes in redox potential and spin equilibrium in cytochrome P450CAM. Biochemistry, 28:917–922. 1989.
118.
RaagR, SwansonBA, PoulosTL, Ortiz de MontellanoPR. Formation, crystal structure, and rearrangement of a cytochrome P450cam iron–phenyl complex. Biochemistry, 29:8119–8126. 1990.
119.
RavichandranKG, BoddupalliSS, HasermannCA, PetersonJA, DeisenhoferJ. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science, 261:731–736. 1993.
120.
RobertsAG, DiazMD, LampeJN, ShiremanLM, GrinsteadJS, DabrowskiMJ, PearsonJT, BowmanMK, AtkinsWM, CampbellAP. NMR studies of ligand binding to P450(ery)F provides insight into the mechanism of cooperativity. Biochemistry, 45:1673–1684. 2006.
RobertsGCK, SutcliffeMJ, ModiS, LianLY, PrimroseWU, WolfCR. Construction of models of P450-substrate complexes by a combination of NMR and homology modelling. FASEB J, 11:A778–A778. 1997.
RupasingheSG, DuanH, SchmidtHLF, BertholdDA, RienstraCM, SchulerMA. High-yield expression and purification of isotopically labeled cytochrome P450 monooxygenases for solid-state NMR spectroscopy. Biochim Biophys Acta-Biomembranes, 1768:3061–3070. 2007.
125.
SabbadinF, JacksonR, HaiderK, TampiG, TurkenburgJP, HartS, BruceNC, GroganG. The 1.5 A structure of XplA-heme, an unusual cytochrome-P450 heme domain that catalyses reductive biotransformation of royal demolition explosive (RDX)J Biol Chem, 284:28467–28475. 2009.
126.
SansenS, YanoJK, ReynaldRL, SchochGA, GriffinKJ, StoutCD, JohnsonEF. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem, 282:14348–14355. 2007.
127.
SavinoC, MontemiglioLC, SciaraG, MieleAE, KendrewSG, JemthP, GianniS, ValloneB. Investigating the structural plasticity of a cytochrome P450: Three dimensional structures of P450 EryK and binding to its physiological substrate. J Biol Chem, 284:291700–29179. 2009.
128.
SchlichtingI, BerendzenJ, ChuK, StockAM, MavesSA, BensonDE, SweetRM, RingeD, PetskoGA, SligarSG. The catalytic pathway of cytochrome P450cam at atomic resolution. Science, 287:1615–1622. 2000.
129.
SchlichtingI, JungC, SchulzeH. Crystal structure of cytochrome P450cam complexed with the (1S)-camphor enantiomer. FEBS Lett, 415:253–257. 1997.
130.
SchochGA, YanoJK, SansenS, DansettePM, StoutCD, JohnsonEF. Determinants of cytochrome P450 2C8 substrate binding: Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem, 283:17227–17237. 2008.
131.
ScottEE, HeYA, WesterMR, WhiteMA, ChinCC, HalpertJR, JohnsonEF, StoutCD. An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc Natl Acad Sci USA, 100:13196–13201. 2003.
132.
ScottEE, WhiteMA, HeYA, JohnsonEF, StoutCD, HalpertJR. Structure of mammalian cytochrome P4502B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-angstrom resolution. Insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem, 279:27294–27301. 2004.
133.
SevrioukovaIF, LiH, ZhangH, PetersonJA, PoulosTL. Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci USA, 96:1863–1868. 1999.
134.
SewardHE, RoujeinikovaA, McLeanKJ, MunroAW, LeysD. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J Biol Chem, 281:39437–39443. 2006.
135.
ShermanDH, LiS, YermalitskayaLV, KimY, SmithJA, WatermanMR, PodustLM. The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. J Biol Chem, 281:26289–26297. 2006.
136.
ShimizuH, ObayashiE, GomiY, ArakawaH, ParkSY, NakamuraH, AdachiS, ShounH, ShiroY. Proton delivery in NO reduction by fungal nitric-oxide reductase. Cryogenic crystallography, spectroscopy, and kinetics of ferric-NO complexes of wild-type and mutant enzymes. J Biol Chem, 275:4816–4826. 2000.
137.
ShimizuH, ParkSY, ShiroY, AdachiS. X-ray structure of nitric oxide reductase (cytochrome P450nor) at atomic resolution. Acta Crystallogr D Biol Crystallogr, 58:81–89. 2002.
138.
SmithBD, SandersJL, PorubskyPR, LushingtonGH, StoutCD, ScottEE. Structure of the human lung cytochrome P450 2A13. J Biol Chem, 282:17306–17313. 2007.
139.
StrushkevichN, UsanovSA, ParkH–W. Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol, 397:1067–1078. 2010.
140.
StrushkevichN, UsanovSA, PlotnikovAN, JonesG, ParkHW. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol, 380:95–106. 2008.
141.
SugimotoH, ShinkyoR, HayashiK, YonedaS, YamadaM, KamakuraM, IkushiroS, ShiroY, SakakiT. Crystal structure of CYP105A1 (P450SU-1) in complex with 1alpha,25-dihydroxyvitamin D3. Biochemistry, 47:4017–4027. 2008.
142.
ToshaT, YoshiokaS, IshimoriK, MorishimaI. L358P mutation on cytochrome P450cam simulates structural changes upon putidaredoxin binding. The structural changes trigger electron transfer to oxy-P450cam from electron donors. J Biol Chem, 279:42836–42843. 2004.
143.
ToshaT, YoshiokaS, TakahashiS, IshimoriK, ShimadaH, MorishimaI. NMR study on the structural changes of cytochrome P450cam upon the complex formation with putidaredoxin. Functional significance of the putidaredoxin-induced structural changes. J Biol Chem, 278:39809–39821. 2003.
144.
VerrasA, AlianA, de MontellanoPR. Cytochrome P450 active site plasticity: attenuation of imidazole binding in cytochrome P450(cam) by an L244A mutation. Protein Eng Des Sel, 19:491–496. 2006.
145.
VidakovicM, SligarSG, LiH, PoulosTL. Understanding the role of the essential Asp251 in cytochrome P450cam using site-directed mutagenesis, crystallography, and kinetic solvent isotope effect. Biochemistry, 37:9211–9219. 1998.
146.
vonWachenfeldtC, RichardsonTH, CosmeJ, JohnsonEF. Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modifications of its N-terminus. Arch Biochem Biophys, 339:107–114. 1997.
147.
WangB, ZhouSF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem, 16:4066–4218. 2009.
148.
WangY, ChenH, MakinoM, ShiroY, NaganoS, AsamizuS, OnakaH, ShaikS. Theoretical and experimental studies of the conversion of chromopyrrolic acid to an antitumor derivative by cytochrome P450 StaP: The catalytic role of water molecules. J Am Chem Soc, 131:6748–6762. 2009.
149.
WeiJY, PochapskyTC, PochapskySS. Detection of a high-barrier conformational change in the active site of cytochrome P450(cam) upon binding of putidaredoxin. J Am Chem Soc, 127:6974–6976. 2005.
150.
WenB, DoneanuCE, GartnerCA, RobertsAG, AtkinsWM, NelsonSD. Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole: Identification of modification sites by mass spectrometry. Biochemistry, 44:1833–1845. 2005.
151.
WesterMR, JohnsonEF, Marques-SoaresC, DansettePM, MansuyD, StoutCD. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: Evidence for multiple substrate binding modes. Biochemistry, 42:6370–6379. 2003.
152.
WesterMR, JohnsonEF, Marques-SoaresC, DijolsS, DansettePM, MansuyD, StoutCD. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: Evidence for an induced fit model of substrate binding. Biochemistry, 42:9335–9345. 2003.
153.
WesterMR, YanoJK, SchochGA, YangC, GriffinKJ, StoutCD, JohnsonEF. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem, 279:35630–35637. 2004.
154.
WhitehouseCJ, BellSG, YangW, YorkeJA, BlanfordCF, StrongAJ, MorseEJ, BartlamM, RaoZ, WongLL. A highly active single-mutation variant of P450BM3 (CYP102A1)Chembiochem, 10:1654–1656. 2009.
WilliamsPA, CosmeJ, SridharV, JohnsonEF, McReeDE. Microsomal cytochrome P4502C5: comparison to microbial P450s and unique features. J Inorg Biochem, 81:183–190. 2000.
157.
WilliamsPA, CosmeJ, WardA, AngoveHC, Matak VinkovicD, JhotiH. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 424:464–468. 2003.
158.
XuLH, FushinobuS, IkedaH, WakagiT, ShounH. Crystal structures of cytochrome P450 105P1 from Streptomyces avermitilis: Conformational flexibility and histidine ligation state. J Bacteriol, 191:1211–1219. 2009.
159.
YanoJK, BlascoF, LiH, SchmidRD, HenneA, PoulosTL. Preliminary characterization and crystal structure of a thermostable cytochrome P450 from Thermus thermophilus. J Biol Chem, 278:608–616. 2003.
160.
YanoJK, DentonTT, CernyMA, ZhangX, JohnsonEF, CashmanJR. Synthetic inhibitors of cytochrome P450 2A6: Inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem, 49:6987–7001. 2006.
161.
YanoJK, HsuMH, GriffinKJ, StoutCD, JohnsonEF. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol, 12:822–823. 2005.
162.
YanoJK, KooLS, SchullerDJ, LiH, Ortiz de MontellanoPR, PoulosTL. Crystal structure of a thermophilic cytochrome P450 from the archaeon Sulfolobus solfataricus. J Biol Chem, 275:31086–31092. 2000.
163.
YanoJK, WesterMR, SchochGA, GriffinKJ, StoutCD, JohnsonEF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J Biol Chem, 279:38091–38094. 2004.
164.
YaoH, McCulloughCR, CostacheAD, PullelaPK, SemDS. Structural evidence for a functionally relevant second camphor binding site in P450cam: Model for substrate entry into a P450 active site. Proteins-Structure Function Bioinform, 69:125–138. 2007.
165.
YasutakeY, ImotoN, FujiiY, FujiiT, ArisawaA, TamuraT. Crystal structure of cytochrome P450 MoxA from Nonomuraea recticatena (CYP105)Biochem Biophys Res Commun, 361:876–882. 2007.
166.
YeomH, SligarSG, LiH, PoulosTL, FulcoAJ. The role of Thr268 in oxygen activation of cytochrome P450BM-3. Biochemistry, 34:14733–14740. 1995.
167.
ZerbeK, PylypenkoO, VitaliF, ZhangW, RousetS, HeckM, VrijbloedJW, BischoffD, BisterB, SussmuthRD, PelzerS, WohllebenW, RobinsonJA, SchlichtingI. Crystal structure of OxyB, a cytochrome P450 implicated in an oxidative phenol coupling reaction during vancomycin biosynthesis. J Biol Chem, 277:47476–47485. 2002.
168.
ZhangH, ImSC, WaskellL. Cytochrome b5 increases the rate of catalysis by cytochrome P4502B4. Acta Pharmacologica Sinica, 27:213–213. 2006.
169.
ZhangHM, MyshkinE, WaskellL. Role of cytochrome b(5) in catalysis by cytochrome P4502B4. Biochem Biophys Res Commun, 338:499–506. 2005.
170.
ZhangW, PochapskySS, PochapskyTC, JainNU. Solution NMR structure of putidaredoxin-cytochrome P450cam complex via a combined residual dipolar coupling-spin labeling approach suggests a role for Trp106 of putidaredoxin in complex formation. J Mol Biol, 384:349–363. 2008.
171.
ZhaoB, GuengerichFP, BellamineA, LambDC, IzumikawaM, LeiL, PodustLM, SundaramoorthyM, KalaitzisJA, ReddyLM, KellySL, MooreBS, StecD, VoehlerM, FalckJR, ShimadaT, WatermanMR. Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem, 280:11599–11607. 2005.
172.
ZhaoB, GuengerichFP, VoehlerM, WatermanMR. Role of active site water molecules and substrate hydroxyl groups in oxygen activation by cytochrome P450 158A2: A new mechanism of proton transfer. J Biol Chem, 280:42188–42197. 2005.
173.
ZhaoB, LambDC, LeiL, KellySL, YuanH, HacheyDL, WatermanMR. Different binding modes of two flaviolin substrate molecules in cytochrome P450 158A1 (CYP158A1) compared to CYP158A2. Biochemistry, 46:8725–8733. 2007.
174.
ZhaoB, LeiL, VassylyevDG, LinX, CaneDE, KellySL, YuanH, LambDC, WatermanMR. Crystal structure of albaflavenone monooxygenase containing a moonlighting terpene synthase active site. J Biol Chem, 2009.
175.
ZhaoY, SunL, MuralidharaBK, KumarS, WhiteMA, StoutCD, HalpertJR. Structural and thermodynamic consequences of 1-(4-chlorophenyl)imidazole binding to cytochrome P450 2B4. Biochemistry, 46:11559–11567. 2007.
176.
ZhaoYH, WhiteMA, MuralidharaBK, SunL, HalpertJR, StoutCD. Structure of microsomal cytochrome P4502B4 complexed with the antifungal drug bifonazole. Insight into P450 conformational plasticity and membrane interaction. J Biol Chem, 281:5973–5981. 2006.
177.
ZhouSF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab, 9:310–322. 2008.
178.
ZhouSF, ZhouZW, YangLP, CaiJP. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem, 16:3480–3675. 2009.
179.
ZvelebilM, WolfCR, SternbergMJE. A predicted 3-dimensional structure of human cytochrome. Implications for substrate specificity. Protein Eng, 4:271–282. 1991.
